Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

Cyclophosphamide 910 Carboplatin 787 pembrolizumab 746 Paclitaxel 744 Bevacizumab 716 Cisplatin 708 Gemcitabine 621 Docetaxel 584 Rituximab 558 Radiotherapy 548 Dexamethasone 511 Nivolumab 491 Doxorubicin 445 Fluorouracil 392 Capecitabine 382 Etoposide 358 Pemetrexed 338 Cytarabine 335 Oxaliplatin 335 Lenalidomide 328 Prednisone 327 Erlotinib Hydrochloride 323 fludarabine phosphate 316 Trastuzumab 305 Leucovorin 299 fludarabine 296 Vincristine 288 Bortezomib 284 Filgrastim 284 Cetuximab 277

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × 177Lu-octreotide, DOTA(0)-Tyr(3)- × Clear all

NCT03049189 2026-04-06

COMPETE

ITM Solucin GmbH

Phase 3 Active not recruiting

324 enrolled 15 charts

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡